Human 4-1BB / TNFRSF9 (24-86) Protein, His Tag

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 8.7 kDa. The protein migrates as 13 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q07011-1

Expression Region

Leu 24 - Cys 86

Host

HEK293

Target

4-1BB

Conjugation

Unconjugated

Tag

C-10xHis

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Human 4-1BB / TNFRSF9 (24-86), His Tag (Cat. No. 41B-H52H9) at 2 μg/mL (100 μL/well) can bind UreluMab, Human IgG4 with a linear range of 0.1-2 ng/mL (QC tested).